MediVas, LLC Announces Positive Preclinical Ferret Data Against H5N1

MediVas, LLC, today announced
promising data from a preclinical H5N1 vaccine study in ferrets performed
at Battelle Memorial Institute's Medical Research and Evaluation Facility
in Columbus, Ohio. For this study, MediVas utilized its novel, synthetic
subunit vaccine, which provides an alternative to traditional egg-based
vaccines. The vaccine used the company's patented biodegradable polymer
technology in a particle form with purified recombinant hemagglutinin (HA)
and nucleoprotein (NP) from the A/Vietnam/1203/2004 virus. This technology
allows MediVas to produce a vaccine against any mutated influenza virus in
as a short as five weeks.



Commenting on the results, Kenneth W. Carpenter, MediVas' President and
CEO said, "These outstanding results represent a significant achievement in
the development of our next-generation pandemic flu vaccine. These data
validate our novel technology and, in particular, our lead intranasal
formulation, which showed a 100% survival rate, presents a meaningful
advance in vaccine technology. With the high antibody response and
exceptional survival results achieved across all formulations in this
study, coupled with our ability for low cost manufacture, storage and
transport of our subunit vaccines, MediVas is poised to deliver a
breakthrough in the fight against avian and seasonal flu."



About MediVas: Since its founding in 1998, MediVas has had one simple
goal -- to change the way that pharmaceuticals are delivered. From small
molecule drugs to whole proteins, MediVas has developed a novel platform
technology that provides solutions to meet each challenge. MediVas polymers
are the first of a new generation of absorbable and biocompatible drug and
biologic delivery platforms. MediVas is utilizing its novel polymer
technology in collaboration with some of the world's largest pharmaceutical
and medical device companies, as well as our own internal product
development efforts. Using this platform technology, MediVas is currently
focusing its development efforts on the delivery of biologics.


MediVas, LLC

medivas